Search
for
Sort by
Research
570-600 / 1000+ resultsresearch MP24-09 MEN WITH AN IMPROVEMENT IN URINARY SYMPTOMS HAVE A LOWER RISK OF MORTALITY
Men with better urinary symptoms have a lower risk of death.
research Faculty Opinions recommendation of Mesotherapy with Bicalutamide: A New Treatment for Androgenetic Alopecia.
Bicalutamide mesotherapy improved hair density in women with hair loss and was well received.
research Mesotherapy with dutasteride for androgenetic alopecia: a concise review of the literature
The document concludes that injecting dutasteride into the skin (mesotherapy) can effectively treat common hair loss in both men and women.
research Combination Therapy with 308-nm Excimer Laser, Compound Glycyrrhizin, and Tacrolimus for Pediatric Facial and Cervical Vitiligo
The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.
research Efficacy and tolerability of oral bicalutamide in forty postmenopausal women with female pattern hair loss: a retrospective study
Bicalutamide may improve hair growth in postmenopausal women with mild side effects.
research Editorial comment
Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.
research Alopecia universalis with IL-12-RB1 and STAT4 mutations effectively treated with upadacitinib
Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
research Long-term hair loss associated with brentuximab vedotin–containing chemotherapy and its psychosocial impact: A retrospective observational study conducted at the Royal Marsden Hospital.
Brentuximab vedotin chemotherapy can cause long-term hair loss and emotional distress.
research BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
The combination treatment showed a higher response rate but no significant survival benefits.
research Dermatolojik Problemler ve COVID-19
COVID-19 can cause skin problems and affect dermatology treatments, with recommendations for skin care and cautious use of certain drugs.
research Peripheral MC1R Activation Modulates Immune Responses and is Neuroprotective in a Mouse Model of Parkinson’s Disease
NDP-MSH protects brain cells and reduces inflammation in Parkinson's disease by activating MC1R and involving Tregs.
research Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines
Cell proteomic footprinting enhances cancer vaccine quality by ensuring correct antigen composition.
research Allogeneic Hair Transplantation with Enhanced Survival by Anti-ICAM-1 Antibody with Short-Term Rapamycin Treatment in Nonhuman Primates
Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.
research Lilly arthritis drug approved for alopecia
The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.
research Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata
Farudodstat may help prevent hair loss in alopecia areata by stopping immune attacks on hair follicles.
research Farmácia Aliança - Maia
Dutasteride is more effective than finasteride for hair growth, and sublingual apomorphine quickly improves Parkinson's symptoms.
research 42175 PASI improvement in the first 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE guselkumab clinical trials
Guselkumab significantly improves psoriasis symptoms within 12 weeks.
research Alopecia Universalis: an extremely rare but probable adverse effect of adalimumab
Adalimumab can cause complete hair loss in rare cases.
research Off-label dermatologic uses of IL-23 inhibitors
IL-23 inhibitors may help treat other skin conditions, but more research is needed.
research Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
research LB1011 Cost and access changes with TNFa inhibitor biosimilars entering the market
Biosimilars lower costs but don't significantly improve access.
research Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana
Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
research Topical imiquimod—Be aware of the unexpected
A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.
research The safety profiles of avacopan on microscopic polyangiitis and granulomatosis with polyangiitis: a real-world pharmacovigilance analysis
Avacopan is generally safe, with some minor side effects like nausea and fatigue.
research Dihydrotestosterone Induces Proliferation, Migration, and Invasion of Human Glioblastoma Cell Lines
Dihydrotestosterone increases growth and spread of human brain cancer cells, and blocking its formation might help treat this cancer.
research Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
Apremilast shows promise for several skin conditions but needs more research.
research Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
PLD is an effective and safer alternative for treating breast cancer.
research Supplementary Material for: Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
CD28 is a promising target for treating alopecia areata with belatacept.
research Supplementary Material for: Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
CD28 is a promising target for treating alopecia areata with belatacept.